CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质瘤临床免疫治疗：当前概念、挑战与未来展望
英文原题：Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives.
查看英文原题
Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质瘤是中枢神经系统常见肿瘤之一，现有治疗方法（手术、放疗和化疗）缺乏特异性且预后较差。随着免疫学、细胞生物学和基因组学发展，肿瘤免疫治疗开启了肿瘤治疗新时代，并在晚期黑色素瘤和晚期非小细胞肺癌等其他侵袭性癌症中取得显著成效。目前，胶质瘤免疫治疗临床试验也在迅速推进。本综述总结近年来有前景的免疫治疗方法，回顾临床试验现状，并讨论胶质瘤免疫治疗的挑战和前景。
展开英文摘要原文
Glioma is one of the common tumors in the central nervous system, and its treatment methods (surgery, radiotherapy, and chemotherapy) lack specificity and have a poor prognosis. With the development of immunology, cell biology, and genomics, tumor immunotherapy has ushered in a new era of tumor therapy, achieving significant results in other invasive cancers such as advanced melanoma and advanced non-small cell lung cancer. Currently, the clinical trials of immunotherapy in glioma are also progressing rapidly.
Here, this review summarizes promising immunotherapy methods in recent years, reviews the current status of clinical trials, and discusses the challenges and prospects of glioma immunotherapy.
论文信息
- 作者
- Liu J、Peng J、Jiang J、Liu Y
- 单位
- Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39555054 · DOI 10.3389/fimmu.2024.1476436
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →